[Autoimmune liver disease and its variant].

M. Zeniya

2001-11-01

Abstract:

What problem does this paper attempt to address?

A Serum Metabolomic Analysis for Diagnosis and Biomarker Discovery of Primary Biliary Cirrhosis and Autoimmune Hepatitis.

Jiang-Shan Lian,Wei Liu,Shao-Rui Hao,De-Ying Chen,Yin-Yin Wang,Jian-Le Yang,Hong-Yu Jia,Jian-Rong Huang

DOI: https://doi.org/10.1016/s1499-3872(15)60393-9

IF: 3.355

2015-01-01

Hepatobiliary & Pancreatic Diseases International

Abstract:BACKGROUND:Because of the diversity of the clinical and laboratory manifestations, the diagnosis of autoimmune liver disease (AILD) remains a challenge in clinical practice. The value of metabolomics has been studied in the diagnosis of many diseases. The present study aimed to determine whether the metabolic profiles, based on ultraperformance liquid chromatography-mass spectrometry (UPLC-MS), differed between autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC), to identify specific metabolomic markers, and to establish a model for the diagnosis of AIH and PBC.METHODS:Serum samples were collected from 20 patients with PBC, 19 patients with AIH, and 25 healthy individuals. UPLC-MS data of the samples were analyzed using principal component analysis, partial least squares discrimination analysis and orthogonal partial least squares discrimination analysis.RESULTS:The partial least squares discrimination analysis model (R2Y=0.991, Q2=0.943) was established between the AIH and PBC groups and exhibited both sensitivity and specificity of 100%. Five groups of biomarkers were identified, including bile acids, free fatty acids, phosphatidylcholines, lysolecithins and sphingomyelin. Bile acids significantly increased in the AIH and PBC groups compared with the healthy control group. The other biomarkers decreased in the AIH and PBC groups compared with those in the healthy control group. In addition, the biomarkers were downregulated in the AIH group compared with the PBC group.CONCLUSIONS:The biomarkers identified revealed the pathophysiological changes in AILD and helped to discriminate between AIH and PBC. The predictability of this method suggests its potential application in the diagnosis of AILD.
Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview

Lydia A. Mercado,Fernando Gil-Lopez,Razvan M. Chirila,Denise M. Harnois

DOI: https://doi.org/10.3390/diagnostics14040382

IF: 3.6

2024-02-10

Diagnostics

Abstract:Autoimmune hepatitis is an immune-mediated inflammatory condition of the liver of undetermined cause that affects both sexes, all ages, races, and ethnicities. Its clinical presentation can be very broad, from having an asymptomatic and silent course to presenting as acute hepatitis, cirrhosis, and acute liver failure potentially requiring liver transplantation. The diagnosis is based on histological abnormalities (interface hepatitis), characteristic clinical and laboratory findings (increased aspartate aminotransferase, alanine aminotransferase, and serum IgG concentration), and the presence of one or more characteristic autoantibodies. The large heterogeneity of these clinical, biochemical, and histological findings can sometimes make a timely and proper diagnosis a difficult task. Treatment seeks to achieve remission of the disease and prevent further progression of liver disease. First-line therapy includes high-dose corticosteroids, which are later tapered to decrease side effects, and azathioprine. In the presence of azathioprine intolerance or a poor response to the standard of care, second-line therapy needs to be considered, including mycophenolate mofetil. AIH remains a diagnostic and therapeutic challenge, and a further understanding of the pathophysiological pathways of the disease and the implementation of randomized controlled trials are needed.

medicine, general & internal
S4577 Unmasking the Deceiver: Autoimmune Hepatitis Disguised as Lymphoma

Ahamed Khalyfa,Antonio J. Sanchez,Yasameen Muzahim

DOI: https://doi.org/10.14309/01.ajg.0001047676.18043.7b

2024-10-26

The American Journal of Gastroenterology

Abstract:Autoimmune hepatitis (AIH) is an immune- mediated inflammatory liver disease that can progress to advanced hepatic fibrosis, cirrhosis and liver failure which makes early diagnosis crucial yet challenging as it lacks signature diagnostic features, and sometimes it manifests in a rare presentation like our patient's.

gastroenterology & hepatology
Autoimmune Liver Diseases in Children

Leslie Mataya,Namrata Patel,Ruba K Azzam

DOI: https://doi.org/10.3928/19382359-20181022-02

2018-11-01

Abstract:Autoimmune liver disease remains difficult to diagnose, and distinguishing the various causes is difficult as well. In children, it can present with wide variation, including autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), and the "overlap syndrome" of AIH/PSC, also known as autoimmune sclerosing cholangitis. These liver disorders are thought to be immune-mediated, but their etiology remains unclear. They are not secondary to inherited or acquired diseases and they are not associated with any drugs, so they can only be diagnosed if these other diseases or conditions are excluded. Because there is considerable commonality in the clinical presentation of these diseases but differences in their management, appropriate treatment may be delayed, increasing the risk for liver transplantation. Further education for general pediatricians and trainees is needed. This article reviews the differences between AIH and PSC, as well as the newly recognized overlap syndrome of both of these diseases. [Pediatr Ann. 2018;47(11):e452-e457.].
Unmet Challenges in Immune-Mediated Hepatobiliary Diseases

Ulrich Beuers,M. Eric Gershwin

DOI: https://doi.org/10.1007/s12016-015-8484-9

2015-03-28

Abstract:It is ironic that the liver, which serves a critical function in immune tolerance, itself becomes the victim of an autoimmune attack. Indeed, liver autoimmunity and the autoimmune diseases associated with both innate and adaptive responses to hepatocytes and/or cholangiocytes are models of human autoimmunity. For example, in primary biliary cirrhosis, there exists a well-defined and characteristic autoantibody and considerable homogeneity between patients. In autoimmune hepatitis, there are clinical characteristics that allow a rigorous subset definition and well-defined inflammatory infiltrates. In both cases, there are defects in a variety of immune pathways and including regulatory cells. In primary sclerosing cholangitis, with its characteristic overlap with inflammatory bowel disease, there are unique defects in innate immunity and particular important contribution of lymphoid homing to disease pathogenesis. In these diseases, as with other human autoimmune processes, there is the critical understanding that pathogenesis requires a genetic background, but is determined by environmental features, and indeed the concordance of these diseases in identical twins highlights the stochastic nature of immunopathology. Unfortunately, despite major advances in basic immunology and in immunopathology in these diseases, there remains a major void in therapy. The newer biologics that are so widely used in rheumatology, neurology, and gastroenterology have not yet seen success in autoimmune liver disease. Future efforts will depend on more rigorous molecular biology and systems analysis in order for successful application to be made to patients.

immunology,allergy
Autoimmune Liver Injury and Non-alcoholic Fatty Liver Disease

李晶,王晶桐,常山幸一,刘玉兰

DOI: https://doi.org/10.3969/j.issn.1008-7125.2010.09.005

2010-01-01

Abstract:Autoimmune liver disease(AILD) and non-alcoholic fatty liver disease(NAFLD) are two major types of chronic inflammatory liver diseases that lead to progressive decline of liver function.Both of them are lack of characteristic clinical symptoms and biochemical parameters.As the worldwide popularity of Western lifestyle and the global trend of obesity and NAFLD,autoimmune hepatitis(AIH) and primary biliary cirrhosis(PBC) would be co-existence with NAFLD, which makes the diagnosis more difficult.When the patients have definite NAFLD and unexplained liver function deterioration,the possibility of concurrent AILD should be taken into account.This article summarized the clinical and pathologic features ofNAFLD-AILD co-existenceand explored its possible mechanism.
Complex Interplay Between the Immune System, Metabolism, and Epigenetic Factors in Autoimmune Liver Diseases

Ya‐Fei Xu,Zhi‐Bin Zhao,Ethan P. Yan,Zhe‐Xiong Lian,Weici Zhang

DOI: https://doi.org/10.1002/med4.23

2023-01-01

Abstract:Abstract Autoimmune liver diseases (ALDs) are chronic inflammatory hepatobiliary diseases in which the autoimmune responses directed against liver tissue result in inflammation and tissue damage. There are several types of ALDs, including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, immunoglobulin G4‐related sclerosing cholangitis, and overlap syndromes. Metabolism and epigenetics are both critical components of the development and progression of ALDs. Immunometabolism addresses how metabolic processes influence immune cell development, fate and behavior, and how immune responses impact metabolism. In the context of immunity, epigenetics involves regulating gene expression without altering the DNA sequence. Epigenetic modifications can ultimately result in changes in the immunophenotype. The interplay between the immune system, metabolism, and epigenetic factors is highly complex. A better understanding of this interplay and the regulatory mechanisms involved is crucial to uncover the disease pathogenesis of ALDs and exploring novel therapeutic options. This article provides a comprehensive review of the dysregulation of immunometabolism and epigenetics, as well as the multilevel regulatory mechanisms, underlying the autoimmunity in ALDs.
Autoimmune Hepatitis: From Evolution to Current Status: A Pathologist's Perspective

Puja Sakhuja,Surbhi Goyal

DOI: https://doi.org/10.3390/diagnostics14020210

IF: 3.6

2024-01-19

Diagnostics

Abstract:Autoimmune hepatitis (AIH) is a chronic, relapsing and remitting, immune-mediated liver disease that progresses to cirrhosis if left untreated. A significant number of patients may present with acute hepatitis or acute liver failure, which are often misdiagnosed as toxic liver injury. AIH shows a preponderance in young women but may be seen in children and the elderly. Diagnosis requires the integration of clinical, biochemical, and serologic parameters, along with supportive liver histology and exclusion of other causes of liver disease. Liver biopsy is a prerequisite for diagnosis of AIH, to assess severity and stage of disease, exclude other entities, and recognize any concurrent morbidities. No single biomarker or histologic feature is pathognomonic for AIH. The diagnostic and histologic criteria have undergone several modifications since the original scoring system was proposed by the International Autoimmune Hepatitis Group (IAIHG) in 1993. Recently, the IAIHG has proposed consensus recommendations for histologic criteria, relevant for both acute and chronic AIH. This review article will describe the evolving diagnostic criteria for AIH, with their limitations and utility, and with an emphasis on the role of liver histology in the diagnosis and management of AIH.

medicine, general & internal
Drug-induced Liver Injury with Autoimmune Phenomena: A Case Report

Xuan JIANG,Zhaoqing LI,Zhipeng ZHANG,Zhifeng WANG,Guoyan ZHANG,Yulan LIU

DOI: https://doi.org/10.3969/j.issn.1008-7125.2010.09.018

2010-01-01

Abstract:null
Autoimmune Hepatitis: A Review of Current Diagnosis and Treatment

Ashima Makol,Kymberly D. Watt,Vaidehi R. Chowdhary

DOI: https://doi.org/10.1155/2011/390916

2011-05-15

Hepatitis Research and Treatment

Abstract:Autoimmune hepatitis (AIH) is a chronic inflammatory disorder characterized by periportal inflammation, elevated immunoglobulins, autoantibodies, and a dramatic response to immunosuppression. An environmental agent is hypothesized to trigger an immune-mediated attack directed against liver antigens in genetically predisposed individuals. A plethora of clinical presentations can be seen ranging from chronic indolent disease to fulminant hepatic failure, and diagnosis requires exclusion of other causes of liver disease. Corticosteroid therapy must be instituted early and modified in an individualized fashion. Treatment decisions are often complicated by the diverse clinical manifestations, uncertainty about natural history, evolving ideas about treatment end points, and a multitude of alternative immunosuppressive agents. Achieving normal liver tests and tissue is the ideal treatment end point, but needs to be weighed against the risk of side effects. Decompensated patients may benefit from early liver transplantation. Long-term prognosis is excellent with early and aggressive initiation of therapy. Our paper discusses AIH, giving a detailed overview of its clinical presentation, risk factors, immunopathogenesis, up-to-date diagnostic criteria, current updates in therapy with a brief discussion of AIH in pregnancy, and long-term implications for cirrhosis and hepatocellular carcinoma in AIH patients.
Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda

Marcial Sebode,Johannes Hartl,Diego Vergani,Ansgar W. Lohse,,

DOI: https://doi.org/10.1111/liv.13458

IF: 8.754

2017-05-18

Liver International

Abstract:Autoimmune hepatitis is a chronic inflammatory liver disease. Unknown triggers lead to a mainly T cell-mediated immune response targeting the liver, the main auto-antigen of which has not been identified yet. The diagnosis of autoimmune hepatitis is based on the elevation of immunoglobulin G/hypergammaglobulinemia, detection of characteristic autoantibodies as well as a typical pattern on liver histology. Exclusion of other causes of hepatitis and response to immunosuppressive treatment support the diagnosis of autoimmune hepatitis. The mainstay of autoimmune hepatitis treatment has, from its first description to the current time, consisted of predniso(lo)ne to induce remission, in combination with azathioprine, which is used to maintain it. Nonetheless, side effects and non-response with ongoing inflammation despite standard therapy demand treatment alternatives. Only through a better understanding of the pathogenesis of autoimmune hepatitis can a more selective and effective treatment be offered to patients in the future. Until this goal is reached, improvement of diagnostic approaches and optimization of current therapy rank highest on the research agenda for autoimmune hepatitis.

gastroenterology & hepatology
Autoimmune Hepatitis—Immunologically Triggered Liver Pathogenesis—Diagnostic and Therapeutic Strategies

Elisabeth Sucher,Robert Sucher,Tanja Gradistanac,Gerald Brandacher,Stefan Schneeberger,Thomas Berg

DOI: https://doi.org/10.1155/2019/9437043

IF: 4.4929

2019-11-25

Journal of Immunology Research

Abstract:Autoimmune hepatitis (AIH) is a severe liver disease that arises in genetically predisposed male and female individuals worldwide. Diagnosis of AIH is made clinically applying diagnostic scores; however, the heterotopic disease phenotype often makes a rapid determination of disease challenging. AIH responds favorably to steroids and pharmacologic immunosuppression, and liver transplantation is only necessary in cases with acute liver failure or end-stage liver cirrhosis. Recurrence or development of de novo AIH after transplantation is possible, and treatment is similar to standard AIH therapy. Current experimental investigations of T cell-mediated autoimmune pathways and analysis of changes within the intestinal microbiome might advance our knowledge on the pathogenesis of AIH and trigger a spark of hope for novel therapeutic strategies.

immunology
Autoimmune Liver Disease Associated Uveitis: An Extrahepatic Manifestation or a Polyautoimmunity Phenomenon? Case Reports

Laura Zarate-Pinzón,Gabriela Flórez-Esparza,Camilo Andrés Rodríguez-Rodríguez,Luis A. Diez-Bahamón,Germán Mejía-Salgado,Carlos Cifuentes-González,Alejandra de-la-Torre

DOI: https://doi.org/10.1080/09273948.2024.2333391

2024-04-04

Ocular Immunology and Inflammation

Abstract:Purpose To report two cases of non-granulomatous unilateral anterior uveitis in two female patients associated with autoimmune liver diseases (ALD), emphasizing the possibility of this rare coexistence as a polyautoimmunity phenomenon.

ophthalmology
Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts

Palak J Trivedi,Gideon M Hirschfield,David H Adams,John M Vierling,Palak J. Trivedi,Gideon M. Hirschfield,David H. Adams,John M. Vierling

DOI: https://doi.org/10.1053/j.gastro.2024.01.049

IF: 29.4

2024-02-01

Gastroenterology

Abstract:Autoimmune liver diseases include primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis, a family of chronic immune-mediated disorders that target hepatocytes and cholangiocytes. Treatments remain nonspecific, variably effective, and noncurative, and the need for liver transplantation is disproportionate to their rarity. Development of effective therapies requires better knowledge of pathogenic mechanisms, including the roles of genetic risk, and how the environment and gut dysbiosis cause immune cell dysfunction and aberrant bile acid signaling. This review summarizes key etiologic and pathogenic concepts and themes relevant for clinical practice and how such learning can guide the development of new therapies for people living with autoimmune liver diseases.

gastroenterology & hepatology
Autoimmune hepatitis: Appraisal of current treatment guidelines

Dhruv Lowe,Savio John

DOI: https://doi.org/10.4254/wjh.v10.i12.911

2018-12-27

World Journal of Hepatology

Abstract:Autoimmune hepatitis affects patients of all ages and gender, across all geographic regions. Although still rare, its incidence and prevalence are increasing. Genetic predisposition conveyed by human leucocyte antigen is a strong risk factor for the disease and may be responsible in part for the wide variation in presentation in different geographic regions. Our understanding of the underlying pathogenic mechanisms is evolving and may lead to development of more targeted immunotherapies. Diagnosis is based on elevated levels of serum aminotransferases, gamma globulins, autoantibodies and characteristic findings on histology. Exclusion of other causes of chronic hepatitis is important. Although undiagnosed disease is associated with poor outcomes, it is readily treatable with timely immunosuppressive therapy in the majority of patients. International guidelines are available to guide management but there exists a disparity in the standard treatment regimens. This minireview aims to review the available guidelines and summarize the key recommendations involved in management of this complex autoimmune disease.
The Gut Microbiota: A Novel Player in Autoimmune Hepatitis

Zilu Cheng,Ling Yang,Huikuan Chu

DOI: https://doi.org/10.3389/fcimb.2022.947382

2022-07-11

Abstract:Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease distributed globally in all ethnicities with increasing prevalence. If left untreated, the disease will lead to cirrhosis, liver failure, or death. The intestinal microbiota is a complex ecosystem located in the human intestine, which extensively affects the human physiological and pathological processes. With more and more in-depth understandings of intestinal microbiota, a substantial body of studies have verified that the intestinal microbiota plays a crucial role in a variety of digestive system diseases, including alcohol-associated liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). However, only a few studies have paid attention to evaluate the relationship between AIH and the intestinal microbiota. While AIH pathogenesis is not fully elucidated yet, some studies have indicated that intestinal microbiota putatively made significant contributions to the occurrence and the development of AIH by triggering several specific signaling pathways, altering the metabolism of intestinal microbiota, as well as modulating the immune response in the intestine and liver. By collecting the latest related literatures, this review summarized the increasing trend of the aerobic bacteria abundance in both AIH patients and AIH mice models. Moreover, the combination of specific bacteria species was found distinct to AIH patients, which could be a promising tool for diagnosing AIH. In addition, there were alterations of luminal metabolites and immune responses, including decreased short-chain fatty acids (SCFAs), increased pathogen associated molecular patterns (PAMPs), imbalanced regulatory T (Treg)/Th17 cells, follicular regulatory T (TFR)/follicular helper T (TFH) cells, and activated natural killer T (NKT) cells. These alterations participate in the onset and the progression of AIH via multiple mechanisms. Therefore, some therapeutic methods based on restoration of intestinal microbiota composition, including probiotics and fecal microbiota transplantation (FMT), as well as targeted intestinal microbiota-associated signaling pathways, confer novel insights into the treatment for AIH patients.
Metabolomics‐based Researches in Autoimmune Liver Disease: A Mini‐Review

Nurmeen Adil,Amna Jabbar Siddiqui,Syed Ghulam Musharraf

DOI: https://doi.org/10.1111/sji.13208

2022-07-26

Scandinavian Journal of Immunology

Abstract:Metabolomics offers a promising approach to studying metabolites in the biological system. It offers new opportunities to assess the disease progression and biomarker selection and also provides a pathophysiological understanding of the disease. Autoimmune liver disease is a major public health concern worldwide. Three main categories of this disease include autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). Their pathogenesis is poorly understood till now. If not treated properly then it will eventually lead to liver cirrhosis and ultimately liver failure occurs. This review summarizes a comprehensive overview of human and animal studies intended to identify the role of metabolomics in all three types of autoimmune liver disease so far. Furthermore, a detailed discussion has been carried out on the disturbed metabolic pathways, including carbohydrate, amino acid, fatty acids, lipids, and bile acid metabolism. Till now, limited work has been done regarding the diagnostic assessment, type of therapy, and disease management for each type. Further research should be conducted to grasp this disease at an earlier stage and to prevent disease‐related complications.

immunology
Detection of Autoantibodies in Chronic Liver Disease and Its Correlation with Autoimmune Liver Diseases

Huang Jiaquan,Zheng Zhixiang,Huang Tiejun

DOI: https://doi.org/10.3870/j.issn.1672-0741.2006.02.015

2006-01-01

Abstract:Objective To investigate the positive rate of autoantibodies and autoimmune liver diseases in patients with chronic liver diseases and its clinical significance.Methods Three hundred and sixty-seven patients with abnormal liver function were chosen and divided into 4 groups: chronic hepatitis B(HBV) group;chronic hepatitis C(HCV) group;autoimmune liver diseases(AID) group;other group.Anti-nuclear antibody(ANA),anti-smooth muscle antibody(SMA),anti-mitochondral antibody(AMA),perinuclear anti-neutrophil cytoplasmic antibodies(pANCA) and cANCA were tested by indirect immunofluorescence.Anti-liver/kidney microsomal type 1(anti LKM-1),anti-soluble liver antigen/live pancreatic antigen(anti-SLA/LP),antibody to liver cytosol type 1(anti LC-1) and subtype 2 of AMA(M2) were tested by Western blot.Results In these 367 cases,9.81 %,10.90 %,7.63 % and 4.90 % were diagnosed as having PBC,AIH,PSC and AIH/PBC respectively.There was significant difference in the positive rate of ANA,AMA,M2 and pANCA among the groups.The overall positive rate of autoantibodies was 20.41 %.The serum levels of AST and TBIL in HBV ANA positive group were significantly higher than in ANA negative group(P<0.05).Conclusion The detection for autoantibodies to liver antigens,ANA,pANCA,cANCA,AMA and subtype 2 of AMA is helpful for diagnosis and differential diagnosis of autoimmune liver diseases.
Evaluation of autoimmune liver disease natural history in patients referred to Middle East Liver Diseases (MELD) center

Seyed Erfan Mehdi Nejad,Mohammad Heiat,Mohammad Javanbakht,Seyed Moayed Alavian,Mohammad Ali Abyazi Haris

DOI: https://doi.org/10.1186/s12876-023-03105-7

2024-01-05

BMC Gastroenterology

Abstract:Autoimmune liver diseases (AILD) are increasing and common forms of chronic liver disease (CLD) with different clinical responses and characteristics which can result in cirrhosis. This study aimed to investigate the natural history and characteristics of AILD in an Iranian population.

gastroenterology & hepatology
Exploring the Pathogenesis of Autoimmune Liver Diseases from the Heterogeneity of Target Cells

Zi-Xuan Qiu,Lin-Xiang Huang,Xiao-Xiao Wang,Zi-Long Wang,Xiao-He Li,Bo Feng

DOI: https://doi.org/10.14218/JCTH.2023.00531

2024-01-01

Journal of Clinical and Translational Hepatology

Abstract:The incidence of autoimmune liver diseases (ALDs) and research on their pathogenesis are increasing annually. However, except for autoimmune hepatitis, which responds well to immunosuppression, primary biliary cholangitis and primary sclerosing cholangitis are insensitive to immunosuppressive therapy. Besides the known effects of the environment, genetics, and immunity on ALDs, the heterogeneity of target cells provides new insights into their pathogenesis. This review started by exploring the heterogeneity in the development, structures, and functions of hepatocytes and epithelial cells of the small and large bile ducts. For example, cytokeratin (CK) 8 and CK18 are primarily expressed in hepatocytes, while CK7 and CK19 are primarily expressed in intrahepatic cholangiocytes. Additionally, emerging technologies of single-cell RNA sequencing and spatial transcriptomic are being applied to study ALDs. This review offered a new perspective on understanding the pathogenic mechanisms and potential treatment strategies for ALDs.

[Autoimmune liver disease and its variant].

A Serum Metabolomic Analysis for Diagnosis and Biomarker Discovery of Primary Biliary Cirrhosis and Autoimmune Hepatitis.

Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview

S4577 Unmasking the Deceiver: Autoimmune Hepatitis Disguised as Lymphoma

Autoimmune Liver Diseases in Children

Unmet Challenges in Immune-Mediated Hepatobiliary Diseases

Autoimmune Liver Injury and Non-alcoholic Fatty Liver Disease

Complex Interplay Between the Immune System, Metabolism, and Epigenetic Factors in Autoimmune Liver Diseases

Autoimmune Hepatitis: From Evolution to Current Status: A Pathologist's Perspective

Drug-induced Liver Injury with Autoimmune Phenomena: A Case Report

Autoimmune Hepatitis: A Review of Current Diagnosis and Treatment

Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda

Autoimmune Hepatitis—Immunologically Triggered Liver Pathogenesis—Diagnostic and Therapeutic Strategies

Autoimmune Liver Disease Associated Uveitis: An Extrahepatic Manifestation or a Polyautoimmunity Phenomenon? Case Reports

Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts

Autoimmune hepatitis: Appraisal of current treatment guidelines

The Gut Microbiota: A Novel Player in Autoimmune Hepatitis

Metabolomics‐based Researches in Autoimmune Liver Disease: A Mini‐Review

Detection of Autoantibodies in Chronic Liver Disease and Its Correlation with Autoimmune Liver Diseases

Evaluation of autoimmune liver disease natural history in patients referred to Middle East Liver Diseases (MELD) center

Exploring the Pathogenesis of Autoimmune Liver Diseases from the Heterogeneity of Target Cells